Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T

NCT05886257 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Protocol adjustment

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Candonilimab
DRUG: Bevacizumab

Sponsor

Shi Ming